H.Res. 1223 is a simple House resolution that expresses the House of Representatives’ support for designating April as Undiagnosed Awareness Month and April 29 as Undiagnosed Day. The preamble collects findings about the frequency and consequences of undiagnosed conditions, highlights the Undiagnosed Diseases Network (UDN) and the patient-founded Undiagnosed Diseases Network Foundation (UDNF), and cites recent UDN outcomes and the NIH strategic objective to expand UDN capacity.
The resolution is non‑binding and does not create new funding or regulatory obligations. Its practical value lies in signaling congressional recognition of diagnostic gaps, raising public and clinical awareness, and reinforcing policy attention on genomic diagnostics, research coordination, and access issues that stakeholders — notably NIH, clinical sites, patient groups, and payers — will need to address if awareness leads to increased demand for diagnostic services.
At a Glance
What It Does
The resolution recognizes April as Undiagnosed Awareness Month and April 29 as Undiagnosed Day, summarizes findings about undiagnosed and rare diseases, and expresses support for the goals of the awareness designation. It primarily records congressional sentiment rather than imposing legal duties or funding requirements.
Who It Affects
Directly referenced actors include the National Institutes of Health (and its Undiagnosed Diseases Network), the UDN Foundation, clinicians and researchers at UDN clinical sites, patients with undiagnosed conditions, and the broader rare-disease community. Indirectly, payers, diagnostic labs, and health systems could see effects if awareness changes demand for testing and referrals.
Why It Matters
Although symbolic, the resolution amplifies NIH’s stated objective to grow UDN capacity and highlights concrete UDN metrics (diagnoses, novel discoveries, clinical network scale and AI use). That combination can steer attention, incentivize coordination among federal and philanthropic actors, and raise expectations for access and equity in diagnostic services.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
H.Res. 1223 compiles a short list of findings and then states congressional support for designating April as Undiagnosed Awareness Month and April 29 as Undiagnosed Day. The bill’s findings quantify the problem — citing roughly 25 million Americans affected by rare and undiagnosed conditions and an average diagnostic odyssey of over seven years — and describe harms: delayed or inappropriate treatment, psychological stress, and financial strain.
The text highlights the Undiagnosed Diseases Network (UDN), created at NIH in 2015, and notes specific outputs: more than 1,000 people diagnosed, identification of over ninety novel diagnoses, a 24‑site clinical network, and pilot use of artificial intelligence to speed diagnoses. It also recognizes the UDN Foundation (UDNF) as a patient‑driven nonprofit that supports access, research, and community for affected families.Because this is a resolution, it does not appropriate funds or require agencies to act.
Its operational consequence is reputational: it endorses the goals of raising awareness and encouraging equitable access to genomic diagnostics and research participation. That endorsement may translate into practical pressure on NIH, health systems, and payers to prioritize capacity, referral pathways, and reimbursement for genomic testing if public awareness and demand increase.Finally, the resolution references NIH’s fiscal year 2026 strategic plan objective to increase UDN capacity by 2027, tying the symbolic recognition to an existing federal planning goal.
For professionals tracking diagnostic ecosystems, the resolution signals a congressional nod toward expanded UDN activity and broader recognition of undiagnosed patients’ needs.
The Five Things You Need to Know
The resolution designates April as Undiagnosed Awareness Month and April 29 as Undiagnosed Day, and expresses the House’s support for those observances.
The bill is a non‑binding House resolution — it states congressional support and findings but does not create legal duties, funding, or regulatory changes.
The preamble cites roughly 25 million Americans living with rare or undiagnosed diseases and an average diagnostic journey exceeding seven years.
The text highlights UDN output: since 2015 the UDN has diagnosed over 1,000 Americans, discovered more than 90 novel diagnoses, operates through 24 clinical sites, and is implementing AI to enhance diagnostics.
The resolution references NIH’s FY2026 strategic objective to increase UDN capacity and expand access to people who do not typically participate in NIH clinical research by 2027.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Findings on scope, harms, and diagnostic delay
This series of Whereas clauses assembles the factual predicates that justify an awareness designation: prevalence estimates (about 25 million Americans), the long average diagnostic interval (over 7 years), and attendant harms (misdiagnoses, psychological and financial burdens). For practitioners and advocates, these findings codify the problem statement that awareness campaigns and policy responses will point to when arguing for resources or program changes.
Affirms the role and results of the Undiagnosed Diseases Network and its foundation
These clauses summarize the UDN’s evolution and contributions: its creation at NIH in 2015, clinical and research outputs (diagnoses, novel disease discoveries), and a decentralized network model of 24 clinical sites deploying genomic sequencing, model‑organism work, and AI. They also recognize the UDNF as a patient‑driven nonprofit. This matters because the resolution explicitly ties the awareness effort to existing federal and community infrastructure rather than presenting a standalone campaign.
Expresses support for the designation
The operative language is a single resolved clause in which the House supports the ideals and goals of Undiagnosed Awareness Month. Legally and procedurally, this is purely declarative: it commits no federal funding and imposes no reporting or implementation requirements. The practical implication is visibility—Congressional endorsement can lend credibility to advocacy, influence agency priorities, and create momentum for follow‑on policy or funding proposals.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Patients with undiagnosed conditions and their families — increased public attention can improve clinician awareness, referral rates to specialty centers, eligibility for research, and community support networks. The resolution explicitly elevates their visibility and the work of patient advocates.
- UDN clinical sites and researchers — congressional recognition can enhance reputation, ease partnership conversations with funders and hospitals, and support recruitment for research and clinical evaluation across the UDN network.
- UDNF and patient advocacy organizations — the resolution validates their organizing work and can be used to leverage philanthropic support, public outreach, and collaborations with NIH and health systems to expand diagnostic access.
Who Bears the Cost
- National Institutes of Health (reputational and programmatic pressure) — while the bill creates no funding mandate, it references NIH goals and could prompt expectations that NIH accelerate UDN expansion without appropriations tied to that expectation.
- Health systems and specialty clinics — if awareness increases referrals for genetic and diagnostic workups, clinics could face higher demand that requires hiring, training, or reconfiguring care pathways, with budgetary implications.
- Payers and diagnostic laboratories — greater awareness often drives more testing and appeals for coverage; payers may see higher claims for genomic sequencing and related diagnostics, and labs may need to scale capacity or justify utility to payers.
Key Issues
The Core Tension
The central tension is between symbolic recognition — which can mobilize attention and pressure institutions to act — and the lack of concrete commitments to fund, regulate, or operationalize expanded diagnostic capacity; elevating expectations for better access and faster diagnoses without accompanying resources risks widening disparities, straining clinical and lab capacity, and turning well‑intentioned awareness into unmet demand.
The resolution is intentionally symbolic; it endorses awareness and documents congressional findings, but it does not appropriate funds, change statutory authority, or create enforceable obligations. That limits immediate operational impact while raising expectations among patients and advocates for tangible follow‑through from agencies and funders.
Scaling the UDN model — or translating awareness into more equitable access to sequencing, specialist evaluation, or AI‑assisted interpretation — depends on concrete investments (workforce, lab capacity, data infrastructure) and reimbursement policy changes. The bill references NIH’s strategic objective to expand UDN capacity, but leaves open how expansion will be funded, how referral criteria will be set, and how equitable access will be secured across rural, low‑income, and historically underrepresented populations.
The resolution’s praise for AI deployment raises additional implementation questions: validation standards for AI‑assisted diagnostics, data sharing and privacy safeguards across a decentralized network, and the risk of uneven performance across diverse populations. Awareness campaigns can also drive increased demand that outstrips capacity, creating short‑term access bottlenecks or incentivizing low‑value testing if clinicians and patients pursue answers without infrastructure to interpret and act on results.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.